Skip to Main content Skip to Navigation
Journal articles

E2F1 inhibition mediates cell death of metastatic melanoma

Abstract : Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need to develop new therapeutical approaches to bypass resistance and achieve more prolonged responses. In this context, we were interested in E2F1, a transcription factor that plays a major role in the control of cell cycle under physiological and pathological conditions. Here we confirmed that E2F1 is highly expressed in melanoma cells. Inhibition of E2F1 activity further increased melanoma cell death and senescence, both in vitro and in vivo. Moreover, blocking E2F1 also induced death of melanoma cells resistant to BRAF inhibitors. In conclusion, our studies suggest that targeting the E2F1 signaling pathway may be therapeutically relevant for melanoma.
Document type :
Journal articles
Complete list of metadata

Cited literature [32 references]  Display  Hide  Download
Contributor : BERTOLOTTO-BALLOTTI BERTOLOTTO-BALLOTTI Connect in order to contact the contributor
Submitted on : Thursday, April 2, 2020 - 4:10:37 PM
Last modification on : Wednesday, May 25, 2022 - 3:18:37 AM


Publisher files allowed on an open archive



Florian Rouaud, Nedra Hamouda-Tekaya, Michaël Cerezo, Patricia Abbe, Joséphine Zangari, et al.. E2F1 inhibition mediates cell death of metastatic melanoma. Cell Death and Disease, Nature Publishing Group, 2018, 9 (5), pp.527. ⟨10.1038/s41419-018-0566-1⟩. ⟨inserm-02529927⟩



Record views


Files downloads